Gablofen (Baclofen) Patent Expiration, LOE Window & CMS Spending

Gablofen (Baclofen) by Piramal Critical Care: Off-Patent Genericized (AB Competition), 19 AB generics, $11.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPiramal Critical Care
FDA Application & PathwayN022462 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$11.0M
2024 Medicare Part D Spend$131K
2024 Medicaid Spend$10.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel